A treatment tool developed at the University of Strathclyde, the United Kingdom, might increase the number of tests on a solid tumour sample by up to 50 times.
The tool is effective against many haematological cancers but poses difficulties when used to treat solid tumours.
Traditional 2D models, which are currently used, do not reproduce the complexity of the tumours microenvironment, while patients tumour models are costly and labor-intensive; 3D models reproduce significantly better what happens in the body.
A miniaturised treatment platform for CAR-T therapy was developed by the Strathclyde study to evaluate the effectiveness of CAR-T cells. The platform allows for visualization and quantification of how CAR-T cells rapidly targeted, broke up and killed cancer cells without causing significant damage to other cells.
Despite the fact that chemotherapy therapy did not work specifically on cancer cells when combined alone, treatment effectiveness was enhanced when combined with CAR-T cell therapy.
Combination therapies are a great opportunity for cancer medicine, and this technology will assist pharmaceutical companies in their efforts to seek new treatments.
Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow, led by Dr Seth Coffelt, have contributed to the research. The work has been published in the International Journal of Engineering in Medicine and Biology.
Dr Michele Zagnoni, a Reader in the Strathclydes Department ofElectronic and Electrical Engineering, and a recently graduated PhD student, led the study.
Not only cancerous cells, but those surrounding them, are at jeopardy difficulties with assessing solid tumours, according to Dr Zagnoni.
We are developing a technological platform that might speed the development of therapies and provide models that are more representative of what happens in the body than what is currently available.
We provide labs with the ability to conduct tests before going to clinical trials, which can save money and reduce costs efficiently.
CAR-T cell development is costly and patient-derived tissue is a limited resource. We aim to allow 20 to 50 times more experiments to be conducted in these conditions.
The technology will be commercialised byScreenIn3D, a pre-spinout business founded in 2018 by Dr Zagnoni, the company''s CEO, and Alex Sim, its executive chair. Karla Paterson, along with Jolanta Beinarovica, is working for the company as an Application Specialist.